Vanguard Group’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $183M | Buy |
36,071,178
+3,783,201
| +12% | +$19.1M | ﹤0.01% | 1549 |
|
|
2025
Q1 | $171M | Sell |
32,287,977
-1,722,017
| -5% | -$9.11M | ﹤0.01% | 1551 |
|
|
2024
Q4 | $230M | Buy |
34,009,994
+9,737,196
| +40% | +$65.8M | ﹤0.01% | 1481 |
|
|
2024
Q3 | $160M | Buy |
24,272,798
+2,716,252
| +13% | +$17.9M | ﹤0.01% | 1655 |
|
|
2024
Q2 | $162M | Buy |
21,556,546
+5,541,782
| +35% | +$41.6M | ﹤0.01% | 1609 |
|
|
2024
Q1 | $160M | Buy |
16,014,764
+349,554
| +2% | +$3.49M | ﹤0.01% | 1642 |
|
|
2023
Q4 | $154M | Buy |
15,665,210
+158,376
| +1% | +$1.56M | ﹤0.01% | 1641 |
|
|
2023
Q3 | $119M | Buy |
15,506,834
+4,247,002
| +38% | +$32.5M | ﹤0.01% | 1712 |
|
|
2023
Q2 | $84.1M | Buy |
11,259,832
+326,248
| +3% | +$2.44M | ﹤0.01% | 1943 |
|
|
2023
Q1 | $72.9M | Buy |
10,933,584
+876,221
| +9% | +$5.84M | ﹤0.01% | 1985 |
|
|
2022
Q4 | $77.5M | Buy |
10,057,363
+1,676,377
| +20% | +$12.9M | ﹤0.01% | 1947 |
|
|
2022
Q3 | $89.2M | Buy |
8,380,986
+1,393,519
| +20% | +$14.8M | ﹤0.01% | 1855 |
|
|
2022
Q2 | $56.9M | Buy |
6,987,467
+376,090
| +6% | +$3.06M | ﹤0.01% | 2138 |
|
|
2022
Q1 | $47.3M | Buy |
6,611,377
+497,504
| +8% | +$3.56M | ﹤0.01% | 2333 |
|
|
2021
Q4 | $105M | Buy |
6,113,873
+3,401,893
| +125% | +$58.3M | ﹤0.01% | 1961 |
|
|
2021
Q3 | $62.4M | Buy |
2,711,980
+28,873
| +1% | +$664K | ﹤0.01% | 2236 |
|
|
2021
Q2 | $97.9M | Buy |
+2,683,107
| New | +$97.9M | ﹤0.01% | 2011 |
|